Conveners
Hadrontherapy
- Lembit Sihver
-
Ignacio Porras (University of Granada, Spain)14/06/2018, 09:00Hadrontherapy
The features of this experimental form of radiotherapy, its status and some research lines in direct relation to nuclear reactions and mechanisms will be discussed.
Go to contribution page -
Mario Pietro Carante (INFN - National Institute for Nuclear Physics)14/06/2018, 09:30Hadrontherapy
The BIANCA (BIophysical ANalysis of Cell death and chromosome Aberrations) biophysical model [1,2] was extended and systematically applied to a wide range of particle types and energies used in cancer hadrontherapy, and the simulation outcomes were analyzed and shaped in a form suitable for an interface with a radiation transport code like FLUKA. This allowed obtaining a tool capable of...
Go to contribution page -
Alessia Embriaco (INFN - National Institute for Nuclear Physics)14/06/2018, 10:00Hadrontherapy
The accurate evaluation of the dose distribution is an open issue in Hadrontherapy.
Go to contribution page
MONET (Model of ioN dosE for Therapy) is a code for the computation of the 3D dose distribution for protons and Helium beam in water. MONET accounts for all the physical interactions and is divided in two part: the lateral and longitudinal distribution.
For the lateral profile, MONET is based on the Molière... -
Dr Giulia Arico' (CERN)14/06/2018, 10:20Hadrontherapy
Background:
Go to contribution page
Ionizing radiation is exploited in radiotherapy to damage malignant cells' DNA and therefore to cause tumor death. Proton and carbon ion beams are already used since decades in many institutes worldwide, while helium ions are planned to be used in the next future at the Heidelberg Ion-Beam Therapy center in Germany [1, 2].
With increasing mass and charge of the primary beam... -
Michela Marafini (INFN Roma1 - Centro Fermi)14/06/2018, 10:40Hadrontherapy
Particle Therapy uses protons and light ions beams for the treatment of deep-seated solid tumors. Due to the features of energy deposition of charged particles a small amount of dose is released to the healthy tissue in the beam entrance region, while the maximum of the dose is released to the tumor at the end of the beam range, in the Bragg peak region. However, nuclear interactions between...
Go to contribution page